Oncoustics Closes $5M+ Seed Funding
Summary
With this close, Oncoustics added Dr. Fong on behalf of Saltagen, and James Wang of Creative Ventures to its board of directors. The company intends to use the funds to advance its SaMD (software as a medical device) technology for the low-cost assessment of structural diseases at point of care. Led by CEO Beth Rogozinski, Oncoustics applies AI to raw ultrasound signals to do tissue characterization at point of care for low-cost, noninvasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. The solutions for ultrasound will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark). The OnX Liver Assessment Solution has not been cleared for clinical use and is For Investigational Use Only.